GoKawiilOpinions expressed by Entrepreneur contributors are their own.
Listen to this post
Key Takeaways The longevity industry is not short on exciting ideas; it is short on trusted systems that can prove which ones work and help doctors use them responsibly.
Boston’s advantage may be less about branding itself as a longevity capital and more about putting researchers, clinicians, biotech founders, investors and hospitals in the same room.
Earlier this summer, I wrote about a suspicion I had: Boston was quietly becoming one of the most important cities in longevity.
Not because it was competing with Switzerland for luxury longevity clinics or Dubai on medical tourism. My argument was that Boston had something potentially more valuable: the concentration of scientists, clinicians, hospitals, biotech companies and capital required to actually test whether the things being sold in longevity work.
Since then, I’ve been watching Boston Longevity Week take shape.
What began as an interesting collection of events has turned into 11 days of researchers, physicians, pharmaceutical executives, biotech founders, investors and entrepreneurs converging on Boston this October. There are conferences dedicated to biomarkers of aging and brain aging, an AI hackathon, an investor pitch night involving more than 30 venture firms, and a healthy aging symposium.
Then I got to the closing event on the calendar: the Translational Longevity Summit.
That word caught my attention.
... continue reading